Update shared on 08 Nov 2025
Fair value Increased 4.93%Analysts have raised their price target for Collegium Pharmaceutical from $44.60 to $46.80. This reflects improved expectations for profit margins even though projected revenue growth is lower.
What's in the News
- Collegium Pharmaceutical raised its full-year 2025 guidance, now expecting net product revenue between $775 and $785 million. This is an increase from the previous range of $745 to $760 million (Key Developments).
Valuation Changes
- Fair Value: Increased from $44.60 to $46.80, reflecting a higher assessed share price.
- Discount Rate: Risen slightly from 6.79% to 6.96%, suggesting a somewhat higher risk or cost of capital.
- Revenue Growth: Projected to decline more steeply, moving from -0.55% to -3.37%.
- Net Profit Margin: Improved significantly from 18.9% to 32.6%.
- Future P/E: Lowered from 12.0x to 7.5x, indicating expectations for stronger earnings relative to price.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.